NXTS on Nasdaq

Nexentis Technologies Inc.

Nexentis Technologies Inc. is an American pharmaceutical preparations company based in Miami.2 Its shares trade on Nasdaq under the symbol NXTS.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Anixa Biosciences Inc, Clene Inc. or NOMAD POWER SOLUTIONS, INC., or pick any stock.

  • TickerNXTS on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersMiami, United States2
  • Incorporated inNV3
  • Business address156 Fifth Avenue 10Th Floor, Co Earthbound Llc, New York, Ny 10010-77513
  • Filer category, Emerging growth company3
  • Legal formProfit Corporation2
  • LEI5299005CKKRZOMGWYL742
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o VCORP SERVICES, LLC, 701 S. CARSON STREET, SUITE 200, 89701 Carson City, United States2
  • Registered withBusiness Center (Secretary of State), NV202329399102

See how the biggest companies compare on our leaderboards

Bean is in the process of voluntary insolvency proceedings. Currently, Plantify has no business activity and minimal liquidity.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

21.4%Gross margin6
-1563.3%Operating margin7
-2472.9%Net margin7
-20.2%Revenue growth, 20246
-109.3%Return on equity7

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue31¢$165.0K
  • Research and development69¢$369.0K
  • Interest0¢$16

Out of $210.0K in revenue.67 The company lost money this year.

Financial statements

Revenue8910116$210.0K in 2024+19% since 2019
0$200.0K$400.0K$600.0K2019: $175.8K$175.8K20192020: $232.3K$232.3K2020+32%2021: $438.1K$438.1K2021+89%2022: $394.0K$394.0K2022−10%2023: $263.0K$263.0K2023−33%2024: $210.0K$210.0K2024−20%
Gross profit8910116$45.0K in 2024+44% since 2019
0$100.0K$200.0K$300.0K$400.0K2019: $31.3K$31.3K20192020: $188.9K$188.9K2020+504%2021: $302.2K$302.2K2021+60%2022: $235.7K$235.7K2022−22%2023: $208.0K$208.0K2023−12%2024: $45.0K$45.0K2024−78%
Operating income89101167-$3.3M in 2024+70% since 2019
-$8.0M-$6.0M-$4.0M-$2.0M02019: -$1.9M-$1.9M20192020: -$1.3M-$1.3M2020−30%2021: -$4.7M-$4.7M2021+249%2022: -$5.8M-$5.8M2022+24%2023: -$7.6M-$7.6M2023+30%2024: -$3.3M-$3.3M2024−57%
Net income89101167-$5.2M in 2024+163% since 2019
-$8.0M-$6.0M-$4.0M-$2.0M02019: -$2.0M-$2.0M20192020: -$1.6M-$1.6M2020−19%2021: -$4.8M-$4.8M2021+203%2022: -$5.7M-$5.7M2022+19%2023: -$6.5M-$6.5M2023+14%2024: -$5.2M-$5.2M2024−20%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development expenses (Note 17)-$179.0K
General and administrative expenses, exclusive of depreciation and amortization (Note 18)-$5.1M-$3.3M
Change in fair value of contingent consideration$1.1M
Depreciation and amortization (Note 4)-$78.0K
Operating loss-$4.2M-$3.3M
Financing expense, net (Note 19)-$1.5M-$252.0K
Other income (Note 15(7))$1.8M$428.0K
Changes in fair value of investments measured under the fair value option (Notes 6, 7)$351.0K-$1.2M
Net loss before tax-$3.6M-$4.3M
Income taxes$18.0K
Net loss from continuing operation-$3.6M-$4.3M
Net loss from discontinued operations (Note 11)-$561.0K-$1.0M
Net loss-$4.2M-$5.3M
Less: Net loss attributable to non-controlling interests$152.0K$154.0K
Net loss attributable to the Companys stockholders equity-$4.0M-$5.2M
Loss per share from continuing operations (basic) (Note 21)-$3-$22
Loss per share from discontinued operations (basic)-$0-$5
Total loss per share (basic)-$3.54-$27.74
Weighted average number of shares of Common Stock outstanding - basic (Note 21)1.1M shares187.2K shares
Loss per share from continuing operations (diluted)-$8-$22
Loss per share from discontinued operations (diluted)-$0-$5
Total loss per share (diluted)-$8.61-$27.74
Weighted average number of shares of Common Stock outstanding diluted1.3M shares187.2K shares
Other comprehensive loss - Foreign currency translation adjustments-$17.0K
Comprehensive income (loss)-$4.2M-$5.3M
Other comprehensive income (loss) attributable to non-controlling interests$157.0K$154.0K
Comprehensive loss attributable to the Companys stockholders-$4.0M-$5.2M

Compare Nexentis Technologies Inc. with another company

Corporate structure

Nexentis Technologies Inc. sits at the top of its group. 4 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nexentis Technologies Inc.

  • Eun Young Lee Filed SCHEDULE 13G/A on Nexentis Technologies Inc., latest Jul 15, 2026 (2 filings since Mar 23, 2026)
  • Ciro Leonardo Pierri Filed SCHEDULE 13G/A on Nexentis Technologies Inc., latest Feb 24, 2026 (2 filings since Feb 12, 2026)
  • Alon Silberman Filed SCHEDULE 13G on Nexentis Technologies Inc., latest Oct 28, 2025
  • Amir Uziel Filed SCHEDULE 13G/A on Nexentis Technologies Inc., latest May 15, 2025 (4 filings since Feb 7, 2022)
  • Capitalink Ltd. Filed SCHEDULE 13G/A on Nexentis Technologies Inc., latest May 15, 2025 (2 filings since Feb 24, 2025)
  • L.I.A. Pure Capital Ltd Filed SCHEDULE 13G/A on Nexentis Technologies Inc., latest May 15, 2025 (5 filings since Feb 14, 2022)
  • Gleb Fetisov Filed SC 13G on Nexentis Technologies Inc., latest Feb 1, 2024
  • Yaaran Investments Ltd. Filed SC 13G on Nexentis Technologies Inc., latest Jul 31, 2023
  • Plantify Foods, Inc. Filed SC 13G on Nexentis Technologies Inc., latest Apr 10, 2023
  • Nir Ecology Ltd. Filed SC 13G/A on Nexentis Technologies Inc., latest Feb 14, 2022
  • Nir Reinhold Filed SC 13G/A on Nexentis Technologies Inc., latest Feb 14, 2022
  • YAAD consulting & management (1995) Ltd. Filed SC 13G/A on Nexentis Technologies Inc., latest Feb 14, 2022
  • Nexentis Technologies Inc. Miami, Florida, United States
    • MitoCareX Bio Ltd. Subsidiary · Israel
    • NITO Renewable Energy, Inc. Subsidiary · Nevada, United States
    • Save Foods Ltd. Subsidiary · Israel

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nexentis Technologies Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$94.0K7 Dec 31, 2025$292.0K6 Dec 31, 2024−67.8%
Accumulated depreciation$68.0K7 Dec 31, 2025$244.0K6 Dec 31, 2024−72.1%
Property and equipment, net$26.0K7 Dec 31, 2025$48.0K6 Dec 31, 2024−45.8%
Operating-lease assets (leased space)$16.0K7 Dec 31, 2025$8.0K7 Dec 31, 2024+100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.8M7 Dec 31, 2025$1.9M7 Dec 31, 2024+99.3%
Marketable securities, current$239.0K7 Dec 31, 2025$307.0K7 Dec 31, 2024−22.1%
Stakes in other companies (equity method)$603.0K7 Dec 31, 2024$1.7M6 Dec 31, 2023−63.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$6.3M7 Dec 31, 2025
Intangible assets, net (excluding goodwill)$4.4M7 Dec 31, 2025

Inventory

ItemLatestA year beforeChange
Inventory, total$21.0K6 Dec 31, 2024$122.0K6 Dec 31, 2023−82.8%

Properties, in its own words

We lease office space in Miami, Florida. We renewed our lease in December 2025 for one year until December 2026, with an option to renew it for an additional one-year term. Our current monthly rent payment is $703.

Additionally, laboratory and office facilities used by our subsidiary MitoCareX are located at the Daren Labs facility in Ness Ziona, Israel. Pursuant to a services agreement extended in October 2025, MitoCareX leases laboratory and office space consisting of several laboratory and office rooms. The agreement is in effect through October 31, 2026. The current monthly payment for the use of these facilities is approximately NIS 33,250 (approximately $10,400) plus VAT.

The rest of Item 2

Our former commercialization and manufacturing operations, which are classified as discontinued operations, were conducted at Neve Yarak (Israel) where we lease approximately 230 square meters of space to run our trials. The lease expired on August 31, 2025, and was extended for an additional one-year period, until August 31, 2026. Our current monthly rent payment is NIS 7,000 (approximately $2,200).

Item 2 of the 10-K filed Mar 31, 2026.5

Leadership

Who has led Nexentis Technologies Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dan Sztybel2019–2020
  2. David Palach2020–now

Chief financial officer

  1. Shlomo Zakai2019
  2. Omri Kanterovich2022
  3. Lital Barda2022–now

Chief operating officer

  1. Neta Matis2022
20202025
Board members and other officers (14)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • MitoCareX Bio Ltd. Israel4
  • NITO Renewable Energy, Inc. Nevada4
  • Save Foods Ltd. Israel4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • N2OFF, Inc.Apr 1, 2024 to Feb 25, 20263
  • Save Foods, Inc.Apr 10, 2023 to Mar 19, 20243
  • Save Foods Inc.Sep 26, 2019 to Apr 10, 20233

Timeline

  1. Oct 6, 20268-K Entered a material agreement34
  2. Sep 3, 20268-K Listing notice or transfer35
  3. Aug 6, 20268-K Change of auditor36
  4. Jun 22, 20268-K Entered a material agreement; Unregistered sale of shares37
  5. Jun 12, 20268-K Entered a material agreement; Unregistered sale of shares38
  6. May 27, 20268-K Entered a material agreement; New debt or obligation39
  7. Apr 30, 20268-K Shareholder vote40
  8. Apr 6, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed41
  9. Mar 17, 20268-K Completed an acquisition or sale42
  10. Feb 26, 20268-K Unregistered sale of shares43
  11. Feb 25, 20268-K Bylaws or fiscal year changed; Regulation FD disclosure44
  12. Jan 13, 20268-K Entered a material agreement; Unregistered sale of shares45
  13. Mar 11, 2023Founded Nexentis Technologies Inc. is founded2
  14. Nov 18, 2020New chief executive David Palach becomes CEO14
  15. Dec 23, 2019New chief executive Dan Sztybel becomes CEO15

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202646

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

231 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 84 major events, 38 insider forms, 23 large holders, 66 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Oct 5, 2026PRE 14A EDGAR
  3. Sep 3, 20268-K EDGAR
  4. Aug 13, 202610-Q EDGAR
  5. Aug 6, 20268-K EDGAR
  6. Jul 17, 2026EFFECT EDGAR
  7. Jul 15, 2026EFFECT EDGAR
  8. Jul 15, 2026SCHEDULE 13G/A EDGAR
  9. Jul 13, 2026S-1 EDGAR
  10. Jul 13, 2026POS AM EDGAR
  11. Jun 23, 2026424B5 EDGAR
  12. Jun 22, 20268-K EDGAR
  13. Jun 15, 2026424B5 EDGAR
  14. Jun 12, 20268-K EDGAR
  15. May 27, 20268-K EDGAR
  16. May 14, 202610-Q EDGAR
  17. Apr 30, 20268-K EDGAR
  18. Apr 29, 2026EFFECT EDGAR
  19. Apr 28, 2026CORRESP EDGAR
  20. Apr 27, 2026UPLOAD EDGAR

The 231 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 8 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 29, 2026Lee Eun Young10% ownerSale127$1.36$173Form 4
Dec 23, 2024Rosenbloom RonenDirectorBuy50,000Form 4
Dec 20, 2023Weiss AmitayDirectorBuy100,000Form 4
Dec 20, 2023Rosenbloom RonenDirectorBuy14,500Form 4
Dec 20, 2023Kalifi Udi OvadiaDirectorBuy14,500Form 4
Dec 20, 2023Berenstein Israel YakovDirectorBuy14,500Form 4
Dec 20, 2023Arbib EliahouDirectorBuy14,500Form 4
Jun 16, 2022Kalifi Udi OvadiaDirectorBuy18,422$3.30$60.8KForm 4
Jun 15, 2022Kalifi Udi OvadiaDirectorBuy9,270$3.16$29.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Yorkville Advisors Global, LP16,409$70.7K0.1%New
Vanguard Fiduciary Trust Co998$4.3K0.0%New
Tower Research Capital LLC (TRC)736$3.2K0.0%New
Hrt Financial LP45,240$1940.0%New
SBI Securities Co., Ltd.32$1380.0%−26
Barclays PLC1$40.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Nexentis Technologies Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNexentis Technologies Inc.1
  • CIK0001789192
  • Employer ID (EIN)26-46846805
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inNevada5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address156 Fifth Avenue 10Th Floor, Co Earthbound Llc, New York, NY 10010-77511
  • Phone9725445613491
  • Shares outstanding1,453,333 as of Aug 13, 202613
  • Public float$6.4M as of Jun 30, 20255
  • AuditorSomekh Chaikin, Tel Aviv, Israel PCAOB ID 10575
  • On EDGAR sinceSep 26, 20191
  • Filings298 in all: 8-K (97), 4 (31), 3 (25), 10-Q (20), UPLOAD (14), CORRESP (10), EFFECT (9), PRE 14A (9)1
    All 34 form types

    DEF 14A (8), SC 13G (8), SC 13G/A (8), 10-K (7), SCHEDULE 13G (7), S-1 (6), S-1/A (6), SCHEDULE 13G/A (5), 424B3 (4), 424B5 (4), 10-12G/A (3), 8-K/A (2), S-3 (2), 10-12G (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14C (1), DEFA14A (1), DEFR14A (1), DEL AM (1), DRS (1), NT 10-Q (1), POS AM (1), PRE 14C (1), PREM14A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Mar 12, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareNXTSNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Nexentis Technologies Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 45 risks under these headings, as written.5

  • Risks Related to Our Financial Condition and Capital Requirements
  • We have a history of operating losses and expect to incur additional losses in the future.
  • We may need to raise significant additional capital, which we may be unable to obtain.
  • Risks Related to Our Business, Industry and Business Operations
  • We may not be successful in our efforts to complete and integrate current and/or future acquisitions, which could disrupt our current business activities and adversely affect our results of operations or future growth.
  • We may not be successful in our efforts to complete and integrate current and/or future joint ventures, which could disrupt our current business activities and adversely affect our results of operations or future growth.
  • Conditions in the global economy, including inflation and recessionary pressures, may adversely affect our business, financial condition and results of operation.
  • Increased attention to environmental, social, and governance (“ESG”) matters and conservation measures may adversely impact our business or that of our manufacturers.
  • Our relationship with our employees could deteriorate, and certain key employees could leave, which could adversely affect our business and results of operations.
  • Risks Related to Business Operations of MitoCareX
  • MitoCareX has no operating history.
  • MitoCareX will require substantial additional capital to finance its operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force it to delay, limit, reduce, or terminate ACSMT development programs, MITOLINE™ related validations and optimizations, commercialization efforts or other operations.
The other 36 risks
  • Raising additional capital may restrict MitoCareX’s operations, or require it to relinquish rights to its ACSMT or other technologies.
  • MitoCareX is early in its development efforts. All of its ACSMT programs are still in the preclinical or discovery stage. Its MITOLINE™ algorithm requires further validations and optimizations. If MitoCareX is unable to successfully develop, obtain regulatory approval, and ultimately commercialize any current or future ACSMT or its MITOLINE™ algorithm, or experience significant delays in doing so, its business will be materially harmed.
  • Risks Related to Intellectual Property
  • If we are unable to secure and maintain patent or other intellectual property protection for our products, our ability to compete may be harmed.
  • If we are unable to prevent unauthorized use or disclosure of our proprietary trade secrets and unprotected know-how, our ability to compete may be harmed.
  • We could become subject to patent and other intellectual property litigation that could be costly, result in the diversion of management’s attention, require us to pay damages and force us to discontinue selling our products.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may experience claims that our products infringe the intellectual property rights of others, which may cause us to incur unexpected costs or prevent us from selling our products or services.
  • Risks Related to Regulatory Compliance
  • If we or our contractors or service providers fail to comply with laws and regulations, we or they could be subject to regulatory actions, which could affect our ability to develop, market and sell our products or future products that we may develop and may harm our reputation in our industry.
  • Regulatory reforms may adversely affect our ability to sell our products profitably.
  • Risks Related to Our Investment in Solar Energy
  • Our investment in the solar energy sector is both for strategic and financial reasons but we may not realize a return on our investments.
  • Climate-Related Risks May Adversely Affect Solterra’s Business and Our Joint Venture Value
  • Regulatory and Compliance Changes May Adversely Impact Solterra’s Operations and Our Joint Venture Value
  • Permitting and Licensing Delays May Impact Solterra’s Project Timelines and Our Joint Venture Value
  • Fluctuations in Electricity Tariffs May Impact Solterra’s Revenue and Our Joint Venture Value
  • Supply Chain and Contractor Disruptions May Delay Solterra’s Projects and Affect Our Joint Venture Value
  • Equipment Malfunctions and Downtime May Impact Solterra’s Operations and Our Joint Venture Value
  • Intense Competition in the Renewable Energy Sector May Affect Solterra’s Market Share and Our Joint Venture Value
  • Joint Venture and Partnership Risks May Affect Solterra’s Projects and Our Joint Venture Value
  • Safety and Operational Risks May Impact Solterra’s Business and Our Joint Venture Value
  • Risks Related to Our Operations in Israel
  • Conditions in Israel and regional instability may adversely affect our operations.
  • We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.
  • It may be difficult to acquire jurisdiction and enforce liabilities against our officers and directors who are based in Israel.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our common stock may be highly volatile.
  • Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our share price to fall.
  • We may need additional capital, and the sale of additional shares or equity or debt securities could result in additional dilution to our stockholders.
  • Nevada law and provisions in our articles of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the market price of our common stock.
  • If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
  • We may be subject to securities litigation, which is expensive and could divert management attention.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our common stock, our stock price and trading volume could decline.
  • We do not anticipate paying any cash dividends in the foreseeable future.
  • General Risk Factors
  • Disruptions to our information technology systems due to cyber-attacks or our failure to upgrade and adjust our information technology systems, may materially impair our operations, hinder our growth and materially and adversely affect our business and results of operations.
  • Failure to comply with anti-bribery, anti-corruption and anti-money laundering laws could subject us to penalties and other adverse consequences.
  • We incur additional increased costs as a result of the listing of our common stock for trading on Nasdaq, and our management is required to devote substantial time to new compliance initiatives and reporting requirements.
  • We face risks related to compliance with corporate governance laws and financial reporting standards.
  • The ongoing conflict in Ukraine may result in market volatility that could adversely affect our business.
  • If we fail to implement and maintain effective internal control over financial reporting, we may be unable to report our financial results accurately or meet our reporting obligations.

Legal proceedings

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58